SGMO Sangamo Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SGMO

Price (delayed)

$1.69

Market cap

$284.74M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.25

Enterprise value

$221.78M

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, cell therapy, and genome engineering.

Highlights
SGMO's debt is down by 12% YoY
The equity fell by 21% YoY and by 4.6% QoQ
The quick ratio has declined by 16% year-on-year and by 3.1% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.sangamo.com
Peers: GILD ALNY AMGN BIIB

Key stats

What are the main financial stats of SGMO
Market
Shares outstanding
168.48M
Market cap
$284.74M
Enterprise value
$221.78M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.94
Price to sales (P/S)
2.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.99
Earnings
Revenue
$111.3M
EBIT
-$191.85M
EBITDA
-$171.29M
Free cash flow
-$243.8M
Per share
EPS
-$1.25
Free cash flow per share
-$1.58
Book value per share
$1.8
Revenue per share
$0.72
TBVPS
$3.07
Balance sheet
Total assets
$562.51M
Total liabilities
$267.55M
Debt
$38.99M
Equity
$294.96M
Working capital
$188.62M
Liquidity
Debt to equity
0.13
Current ratio
2.69
Quick ratio
2.53
Net debt/EBITDA
0.37
Margins
EBITDA margin
-153.9%
Gross margin
100%
Net margin
-172.8%
Operating margin
-180.8%
Efficiency
Return on assets
-31.7%
Return on equity
-61.2%
Return on invested capital
-57.6%
Return on capital employed
-42.6%
Return on sales
-172.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SGMO stock price

How has the Sangamo Therapeutics stock price performed over time
Intraday
-3.98%
1 week
-20.66%
1 month
-42.12%
1 year
-70.66%
YTD
-46.18%
QTD
-46.18%

Financial performance

How have Sangamo Therapeutics's revenue and profit performed over time
Revenue
$111.3M
Gross profit
$111.3M
Operating income
-$201.28M
Net income
-$192.28M
Gross margin
100%
Net margin
-172.8%
The operating income has contracted by 10% YoY and by 8% from the previous quarter
SGMO's operating margin is down by 9% year-on-year and by 9% since the previous quarter
SGMO's net margin is down by 9% QoQ and by 7% YoY
Sangamo Therapeutics's net income has decreased by 8% QoQ and by 8% YoY

Growth

What is Sangamo Therapeutics's growth rate over time

Valuation

What is Sangamo Therapeutics stock price valuation
P/E
N/A
P/B
0.94
P/S
2.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.99
The EPS has declined by 6% since the previous quarter
The price to book (P/B) is 69% lower than the 5-year quarterly average of 3.2 and 55% lower than the last 4 quarters average of 2.2
The equity fell by 21% YoY and by 4.6% QoQ
The stock's P/S is 82% below its 5-year quarterly average of 13.3 and 59% below its last 4 quarters average of 6.0

Efficiency

How efficient is Sangamo Therapeutics business performance
The ROE has contracted by 46% YoY and by 15% from the previous quarter
Sangamo Therapeutics's return on invested capital has decreased by 45% YoY and by 13% QoQ
The company's return on assets fell by 43% YoY and by 15% QoQ
The return on sales has declined by 9% since the previous quarter and by 7% year-on-year

Dividends

What is SGMO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SGMO.

Financial health

How did Sangamo Therapeutics financials performed over time
SGMO's total assets is 110% greater than its total liabilities
SGMO's total liabilities is down by 23% year-on-year and by 6% since the previous quarter
SGMO's total assets is down by 22% year-on-year and by 5% since the previous quarter
SGMO's debt is 87% lower than its equity
The equity fell by 21% YoY and by 4.6% QoQ
SGMO's debt is down by 12% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.